<DOC>
	<DOCNO>NCT00721279</DOCNO>
	<brief_summary>The objective Post Market Surveillance ( PMS ) study evaluate treatment effect pramipexole Restless Legs Syndrome ( RLS ) severity measure International Restless Legs Rating Scale Global Clinical Impression - Improvement , evaluate time reach maintenance dose pramipexole</brief_summary>
	<brief_title>Sifrol ( Pramipexole ) Onset Action Impact : 12-weeks Observational Study Patients With Primary Restless Legs Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Psychomotor Agitation</mesh_term>
	<mesh_term>Restless Legs Syndrome</mesh_term>
	<mesh_term>Pramipexole</mesh_term>
	<criteria>Primary Restless Legs Syndrome ( i.e . idiopathic RLS ) Indication treatment pramipexole Male female patient older 18 year Any contraindication accord Summary Product Characteristics ( SPC ) : hypersensitivity pramipexole excipients Current treatment pramipexole</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>